IMMS GmbH of Ilmenau at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair
Service

IMMS GmbH

Ehrenbergstr. 27, 98693 Ilmenau
Germany

Telephone +49 361 6632541
Fax +49 361 6632501
susette.germer@imms.de

This company is co-exhibitor of
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg e.V.

Hall map

MEDICA 2017 hall map (Hall 3): stand G60

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.02  DNA diagnosis kits
  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.02  DNA diagnosis kits
  • 03.01.02.01  Lab-on-a-chip
  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.14  Rapid tests - clinical chemistry
  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.14  Rapid tests - clinical chemistry
  • 03.01.14.01  Point of care - testing systems

Our products

Product category: Rapid tests - clinical chemistry, Point of care - testing systems

Development of microelectronic sensor systems for quantitative point-of-care tests

Connecting microelectronics and life sciences...
With your know-how in the field of biotechnology as starting point for joint development ventures, we work towards customised microelectronic sensor systems for use in quantitative point-of-care and in-vitro diagnostics. For you as our customer and partner, we bring to bear our range of competencies and our 20+ years of experience in developing and implementing ASICs, application-specific integrated circuits, on semiconductor wafers. We have multi-parameter microelectronics-based platforms which we can adapt to your application's requirements, and are already experienced in joint development of personalised diagnostic systems for infections and early cancer diagnosis.

... for speedier, cheaper and more accurate diagnostic systems
As the basis of our work, we harness off-the-shelf, reasonably priced fabrication techniques and CMOS technology, incorporating them into innovative diagnostic systems. One important focus of our research is the integration of a variety of detection principles into a single electronic sensor to measure biological and chemical features from which full and accurate deductions can be made.  We work in close conjunction with our partners to match the systems to the application, for instance by providing interfaces that are made of biocompatible materials or by accommodating the packaging. All this brings closer a future of point-of-care testing which is fast, reliable, cheap and largely automated.

More Less

Product category: DNA diagnosis kits, Lab-on-a-chip

Lab-on-a-chip: Microelectronics for the development of speedier, cheaper and more accurate diagnostic systems

As the basis of our work, we harness off-the-shelf, reasonably priced fabrication techniques and CMOS technology, incorporating them into innovative diagnostic systems. One important focus of our research is the integration of a variety of detection principles into a single electronic sensor to measure biological and chemical features from which full and accurate deductions can be made.  We work in close conjunction with our partners to match the systems to the application, for instance by providing interfaces that are made of biocompatible materials or by accommodating the packaging. All this brings closer a future of point-of-care testing which is fast, reliable, cheap and largely automated.

More Less

Company news

Date

Topic

Download

Nov 13, 2017

Batteryless RFID sensor chip sends measured data out of aqueous solutions

IMMS demonstrates prototype at MEDICA, Nov 13th – 16th, Hall 3/G60

13th November 2017. At the MEDCIA trade fair in Düsseldorf, Germany, IMMS presents via live-demo a passive RFID microelectronic chip with remote power supply. Placed into aqueous solutions, the chip measures temperature data which is captured and processed by an RFID reader unit. With this energy-efficient chip developed by IMMS, values are being measured and digitised with a power consumption of very few microwatts (approximately 3.5 microwatt). This would facilitate the use of a sensor operable without interruption for at least a 10-year period from a mignon battery with a typical capacity of 1000 mAh. Thanks to this ultra-low power consumption a battery is dispensable: an RFID reader unit generates an electromagnetic field which is sufficient to supply the passive RFID chip with power and to record and send data through containers and liquids over distances of up to four centimetres.

The development is a result of the ADMONT European Union joint project which sees IMMS doing research and development on the design of intelligent in-vitro diagnostic und bioanalytical sensor and actuator systems and which will run until 2019. The RFID-Chip combines high accuracy, energy-efficient operation and cost efficiency. The new digital RFID-coupled temperature sensor acquires values in  the large measuring range from –40 °C to 125 °C with an accuracy of +/–0,5 °C. To reach a power consumption of only 3.5 microwatt, IMMS eliminated analog-to-digital converters which consume much energy. As a substitute, IMMS implemented a time-coded signal processing which allows the conversion of  temperature values into  timing signals. This digital information can be handled with minimised energy consumption.  For a low-cost solution IMMS harnessed off-the-shelf, reasonably priced CMOS technology and developed a single-chip solution with integrated sensors and with embedded electronic signal processing. This chip does not need any further components besides the RFID antenna.

The batteryless principle for RFID sensors which is introduced at the MEDICA is currently being transferred by IMMS to other measurands to lay the foundation for various applications in bioanalysis and beyond.

Funding:

The ADMONT project has revived funding from the ECSEL Joint Undertaking under grant agreement No 661796. This Joint Undertaking has revived support as Innovation Action from the European Union's Horizon 2020 research and innovation programme, the German Federal Ministry of Education and Research (BMBF) and Finland, Sweden, Italy, Austria, Hungary. The IMMS sub-project ”Design of intelligent in vitro diagnostic und bioanalytical sensor and actuator systems“ has revived funding under the reference 16ESE0057.

About IMMS

IMMS serves small and medium-sized industrial enterprises through preliminary research. It acts as their strategic partner in the development of micro-electronic and mechatronic products and of systems technology. This entails devising extremely precise and energy-efficient comprehensive solutions for the fields of automation, semi-conductors, medical technology, life sciences, and environmental or automotive engineering. A further role of IMMS is to contribute research to the technology of a range of industrial techniques: communications, measuring and control technologies and micro-/nano-engineering. For its partners, IMMS is the cutting edge, slicing through the barriers between science and manufacturing, so that in many cases its partners will be five or ten years ahead of the competition. IMMS is thus a veritable bridge between science and industry. The IMMS motto, “Wir verbinden die IT mit der realen Welt”, emphasizes the need and the challenges inherent in connecting IT to the real world. Consequently, the Institute concerns itself with designing and creating sensor and actuator systems, control and feedback systems, and signal processing systems, then also integrating the systems and linking them to their environment. The work is to develop and optimize all the individual system elements, components and circuits and to achieve communication not only between those elements but between them and their environment. Currently, there are 80 staff members working at this Institute, which was founded in 1995 as an associated research institute of the TU.
www.imms.de

More Less

Nov 10, 2017

IRIS®II – Bionic vision system to compensate for blindness – microelectronics for a retinal implant

IMMS presents Pixium Vision‘s epi-retinal system at MEDICA, Nov 13th – 16th, Hall 3/G60

10th November 2017. At the MEDICA trade fair in Düsseldorf, Germany, IMMS will present a Bionic Vision System for the treatment of blindness. The epi-retinal IRIS®II system from Pixium Vision incorporates a biocompatible microelectronic implantable chip developed by IMMS especially for this application. The chip is part of a retinal implant with which people who have lost their sight from retinitis pigmentosa but with an intact optic nerve are learning to partially see again. A camera integrated into the spectacles records images of the environment which are transferred through the pupil to the retinal implant. There, the IMMS chip converts the optical information into an electronic data stream which is passed to the retina stimulator for the excitation of the optic nerve cells to elicit visual perception in the brain. The patients of the IRIS®II European clinical trial are currently learning to interpret the new perception in their re-education program. At MEDICA, IMMS will present the system with which those patients are being equipped and video examples from the study with patients' experiences.

The challenges for microelectronic implants
„Such a retinal implant is a big challenge from an engineering point of view, not only with regards to miniaturisation and functionality“ says Khalid Ishaque, CEO of Pixium Vision, looking back over 15 years of research and development. „Imagine wanting to have a working TV underwater in the Mediterranean Sea, which is warm, moving and salty. It’s kind of similar challenge for such a microelectronic implant in your eye.“ The electronic implant needs to be flexible and function while the eyeball is moving. In addition, it has to operate energy-efficiently and within harmless thermal safety thresholds. Furthermore, in the human body, power supply cannot be delivered with a direct current, usual for such circuits. So for the chip design a solution with alternating voltage had to be found.

IMMS chip translates images to signals for the intact optic nerve
The infrared receiver chip developed by IMMS is implanted into the inner eyeball and translates the incoming information from the optical interface into a current signal which is transferred to the stimulator chip. As essential elements for implementing this functionality IMMS created and tested the photodiode, the control circuit for signal detection and the output driver.
For a minimum energy consumption, for a low heat generation and for a constant operational state IMMS has implemented circuit design concepts which only need a current consumption of less than 120 µA.

IMMS has developed an energy supply for the chip using alternating voltage, which is transformed by a rectifier into an internal direct current exclusively used in the hermetically sealed circuit. For this reason, the evaluation of the supply current could not be run using standard measurements. Therefore, IMMS has developed an especially adapted measuring method with which the value of the supply current is being identified with the use of an inductive current probe.

„IMMS delivered a vital contribution to our goal of restoring partial perception to people with vision loss from retinitis pigmentosa. The chip made by IMMS is the fundamental part of the gateway between the real world to  the eye through the optic nerve and the brain of the patient,“ according to Khalid Ishaque. “But for him, after surgery the hard work starts – which involves retraining the brain.“ For this huge challenge Pixium Vision has been cooperating with multi-disciplinary partners at the cutting edge of neuroscience, physics, optics and mathematics, microsurgery, ophthalmic surgery, and low vision experts. „This global ecosystem of partners is critical to the success on this journey, which was not so long ago considered impossible.“

The future:
Pixium Vision has also been authorized to start a clinical study in Human for PRIMA, a sub-retinal miniaturized wireless implant system to treat advanced atrophic dry-AMD, the most prevalent form of age-related macular degeneration.

More Less

Nov 9, 2017

Mobile rapid tests for prostate and colon cancer – microelectronics measures antigen concentration

IMMS demonstrates functional model at MEDICA trade fair, Nov 13th – 16th, hall 3/G60

9th November 2017. At the MEDCIA trade fair in Düsseldorf, Germany, IMMS will present a mobile microelectronic testing system for early diagnosis of prostate and colon cancer. Via live-demo of a functional model IMMS will illustrate the detection principle the current work is based on and which is carried out in the INSPECT project with four partners  in Thüringen, Germany. It is the role of IMMS to develop the application-specific microelectronics, focussing on signal processing, particularly in the case of very weak signals, and efficient noise suppression for these. These chips are currently being used by the Senova Gesellschaft für Biowissenschaft und Technik mbH to conduct extensive test series with biological samples. The foundation is Senova’s expertise in immunological assays and in biochemical surface functionalisation of chips. Thanks to the combination of immunological testing methods with microelectronics it becomes possible to early, precisely and reliably verify lowest concentrations of cancer biomarkers.

Present rapid tests no more than qualitative
There are certain types of cancer for which the patient’s doctor can test rapidly on the spot, obtaining an immediate result and saving costly, time-consuming lab tests. The present state of the art includes the strip test on which antibody molecules have been deposited. These seeker molecules have a colour marker and will bind the target molecule to them, producing a result within 5 or 10 minutes: the answer is ”yes“ or ”no“ according to the presence of a coloured line. However, varying strength in the colour of this line is not information that the user can interpret. It is also possible for a very pale line to be overlooked. 

Future quantitative rapid tests for exact diagnosis
On the other hand, if it were possible to measure the exact concentration of certain molecules in sample fluids, reliable diagnosis could be achieved. Particularly in the case of cancer of the prostate, there would be a great improvement if the on-site diagnostics could include such quantitative analysis. Although the presence of PSA (prostate-specific antigen) may be an indicator of cancer, it is constantly being produced in the male body. A man less than 50 years old will have a PSA concentration of less than 2.5 ng/ml (the unit is in thousand-millionths of a gram, i.e. in nanograms, per millilitre). At over 70, a man will have a level around 6.5 ng/ml. It is possible for these values to vary independently of age; the cause may be inflammation, mechanical irritation or cancer. If there is a carcinoma developing, the patient’s PSA concentration will be rising continuously. If the PSA concentration could be measured at regular intervals, reliable early diagnosis and early treatment would result.

Microelectronics to measure antigen concentrations in colon and prostate cancer
The biotechnical principles on which the new test system will be based are comparable with those for the strip test. The interaction between antibody and antigen is intended to enable detection of analytes in a sample: PSA in the case of prostate cancer and haemoglobin in the case of colon cancer. To meet the diagnostic needs, the chip must be capable of recognising concentrations of antigens in the range of one nanogram per cubic centimetre. These low concentrations induce very weak fluctuations in the luminous intensity, between 0.01 Bel and 1 Bel.

IMMS has thoroughly investigated the technical feasibility of achieving this level of accuracy for the purpose of cancer diagnosis. As a first step an already available chip originally intended for detecting infectious diseases was  evaluated  to  see  how  it  would  visualise  varying  levels  of  brightness  in  sample fluids where the concentration of particles is known. TMB (tetramethylbenzidine) substrate solutions were deposited on this chip and the TMBs were enriched with HRP (the horseradish  peroxidase  enzyme).  The  chemical  reactions  which  took  place  turned  the  fluids  blue – the lower the concentration, the more slowly.  The  chips  were  used  to measure the gradual attenuation of light  due  to  staining  over  time and  tiniest HRP quantities have already been verified.

For this purpose, 4 sample solutions were used which contained 0 ng/ml, 0.2 ng/ml, 1 ng/ml and 5 ng/ml of HRP respectively. For  each  sample,  on  addition  of  the  specified HRP concentration, a brightness value was recorded for each second over a period of 600 seconds. These recordings proved that the alterations in brightness were  indeed  in  the  range  0.01  Bel  to  1  Bel  and  the  visualised  differences  in  the reaction processes were consonant with expectations. It is intended to rely on this preparatory work in developing correlations for the analyte concentrations which would prove the presence of PSA and haemoglobin to specify requirements for the new chip design.

View on the intermediate state of the mobile microelectronic-based test system
„A point-of-care diagnostic system could be prototyped, allowing bio-medical analyses to be carried out at the premises of the Senova GmbH. The high resolution of the signals and the accurate signal detection made it clear that simple, quick, reliable diagnosis and monitoring of certain cancers is possible,“ says Dr. Friedrich Scholz, Senova Gesellschaft für Biowissenschaft und Technik mbH, about the state of development. „The system is currently being tested for prostate and colon cancer diagnostics. In the future the various sensors on the chip should allow the analysis of a range of parameters so that cancer diagnosis will become ever more reliable and certain and so that the monitoring of individual therapies will become possible.“

Funding:
The INSPECT project was funded by the “Land” of Thüringen and the European Union under the reference 2015 FE 9159.

Partners:
·       CDA GmbH (www.cda.de)
·       iba Institut für Bioprozess- und Analysenmesstechnik e.V. (www.iba-heiligenstadt.de)
·       IMMS Institut für Mikroelektronik- und Mechatronik-Systeme gemeinnützige GmbH (www.imms.de)
·       Senova Gesellschaft für Biowissenschaft und Technik mbH (www.senova.de)
·       X-FAB Semiconductor Foundries AG (www.xfab.com)

About Senova Gesellschaft für Biowissenschaft und Technik mbH
Senova is an internationally active medium-sized and owner-managed company based in Weimar. Senova is specialized in high-quality immunological rapid tests for the detection of proteins, haptens, nucleic acids, microorganisms and viruses. With its powerful research department, extensive methods for quality assurance and quality management and large production capacity for test kits Senova provides its customers with all the tools available to develop, validate, and produce rapid test products successfully. This product and service portfolio is complemented by a well-developed distribution network in human and veterinary diagnostics by our partner Devidia - Deutsche Vitaldiagnostik. Senova rapid tests for point-of-care diagnostic are based on the well-established lateral flow technology or innovative 3D immunofiltration. Senova develops new test systems or establishes new tests on existing platforms on behalf of its clients. The team can take advantage of a wide range of tools and methods which have emerged in recent years through intensive technology development and cooperation with research partners. The company is certified ISO 13 485 and ISO 9001 since 2011 and features a fully certified quality management system. www.senova.de

About IMMS
IMMS serves small and medium-sized industrial enterprises through preliminary research. It acts as their strategic partner in the development of micro-electronic and mechatronic products and of systems technology. This entails devising extremely precise and energy-efficient comprehensive solutions for the fields of automation, semi-conductors, medical technology, life sciences, and environmental or automotive engineering. A further role of IMMS is to contribute research to the technology of a range of industrial techniques: communications, measuring and control technologies and micro-/nano-engineering. For its partners, IMMS is the cutting edge , slicing through the barriers between science and manufacturing, so that in many cases its partners will be five or ten years ahead of the competition. IMMS is thus a veritable bridge between science and industry. The IMMS motto, “Wir verbinden die IT mit der realen Welt”, emphasizes the need and the challenges inherent in connecting IT to the real world. Consequently, the Institute concerns itself with designing and creating sensor and actuator systems, control and feedback systems, and signal processing systems, then also integrating the systems and linking them to their environment. The work is to develop and optimize all the individual system elements, components and circuits and to achieve communication not only between those elements but between them and their environment. Currently, there are 80 staff members working at this Institute, which was founded in 1995 as an associated research institute of the TU. www.imms.de

More Less

Nov 8, 2017

IMMS presents three developments at MEDICA 2017

8th November 2017. At the MEDCIA trade fair in Düsseldorf, Germany, IMMS will present a mobile microelectronic testing system for early cancer diagnosis, microelectronics for the analysis of aqueous solutions with the help of passive RFID sensors and a Bionic Vision System to compensate for blindness. Functional models and prototypes will illustrate the current state of research and development activities on bioanalysis carried out at IMMS. Furthermore, the Institute will introduce a chip development for medical technology which is part of Pixium Vision’s IRIS®II epi-retinal system presently being investigated in clinical studies.   

Functional model for quantitative point-of-care cancer diagnosis with the help of microelectronics
There are certain types of cancer for which the patient’s doctor can test rapidly on the spot, obtaining an immediate result and thus resulting in saving cost and time-consuming lab tests. Present rapid tests are no more than qualitative and produce results confined to ”yes“ or ”no“. For colon and prostate cancer to be diagnosed at a very early stage, IMMS is developing microelectronics coming into direct contact with a sample and being capable of recognising concentrations of antigens in the range of one nanogram per cubic centimetre. Via live-demo of the functional model, IMMS will present the detection principle the current work is based on.

A passive RFID sensor prototype for the analysis of aqueous solutions
IMMS will demonstrate a passive RFID microelectronic chip with remote power supply. Placed into aqueous solutions, the chip measures temperature data which is captured and processed by an RFID reader unit. With this energy-efficient chip developed by IMMS, values are being measured and digitised with a power consumption of very few microwatts (approximately 3.5 microwatt). This would facilitate the use of a sensor operable without interruption for at least a 10-year period from a mignon battery with a typical capacity of 1000 mAh. Thanks to this ultra-low power consumption a battery is dispensable: an RFID reader unit generates an electromagnetic field which is sufficient to supply the passive RFID chip with power and to record and send data through containers and liquids over distance of  up to four centimetres. The batteryless principle for RFID sensors which is introduced at the MEDICA is currently being transferred by IMMS to other measurands. 

IRIS®II – epi-retinal system of Pixium Vision to compensate for blindness 
IMMS has developed a biocompatible microelectronic chip as part of a retinal implant system with which people who have lost their sight from retinitis pigmentosa but with an intact optic nerve are learning to partially see again. A camera integrated into the spectacles records images of the environment which are transferred through the pupil to the retinal implant. There, the IMMS chip converts the optical information into an electronic data stream which is passed to the retina stimulator for the excitation of the optic nerve cells to elicit visual perception in the brain. The patients of the IRIS®II European clinical trial are currently learning to interpret the new perception in their re-education program. At the MEDICA, IMMS will present the system with which those patients are being equipped and video examples from on the study with patients' experiences.

More Less

About us

Company details

Connecting microelectronics and life sciences for speedier, cheaper and more accurate diagnostic systems

IMMS serves its industry and research partners through feasibility studies and preliminary research. The Institute is a strategic partner in the development of microelectronic and mechatronic products and of systems technology.

Our fields of competence

  • Electronics design for single sensors, sensor arrays or   autonomous sensor systems
  • ASIC development for multi-physical detection:
    . Optical sensing
    . Electrical  sensing - amperometric, voltammetric,  
      impedimetric or capacitive
    . Electrochemical sensing (pH, pNa, pO2, ...)
  • Wireless signal detection and transmission to keep biological samples germ-free and intact
  • Development of systems which include both sensors and actuators
IMMS: We connect IT to the real world.

More Less

Company data

Number of employees

50-99

Foundation

1995

Company information as a PDF file